Literature DB >> 24011429

Non-invasive prenatal screening for trisomy 21: what women want and are willing to pay.

E J Joanne Verweij1, Dick Oepkes, Marieke de Vries, M E Elske van den Akker, Eline S van den Akker, Marjon A de Boer.   

Abstract

OBJECTIVE: To investigate the attitude among pregnant women regarding non-invasive prenatal testing (NIPT) for detecting trisomy 21 (T21) and to quantify their willingness to pay for NIPT.
METHODS: A questionnaire was administered to pregnant women who received counselling for first-trimester screening (FTS) in two hospitals and nine midwife practices in the Netherlands.
RESULTS: A total of 147 women completed the questionnaire, yielding a response rate of 43%. If NIPT for detecting T21 were available, 81% stated they would choose to have this test, and 57% of women who elected not to undergo FTS in their current pregnancy would perform NIPT if available. Willingness to pay for NIPT was correlated with age and income, but not education level. The price that participants were willing to pay for NIPT was similar to the current price for FTS.
CONCLUSION: The pregnant women in our study had a positive attitude regarding NIPT for T21, and more than half of the women who rejected prenatal screening would receive NIPT if available. PRACTICE IMPLICATIONS: Due to the elimination of iatrogenic miscarriage, caregivers should be aware that informed decision-making can change with respect to prenatal screening with the introduction of NIPT.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Down syndrome; Informed decision-making; Non-invasive prenatal testing (NIPT); Non-invasive testing; Prenatal screening; Trisomy 21; Willingness to pay

Mesh:

Year:  2013        PMID: 24011429     DOI: 10.1016/j.pec.2013.08.006

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  7 in total

1.  Not-so-free testing for cell-free DNA.

Authors:  Darryl Huang; Karen Lundgard; Michael R Kolber
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

2.  DASAF: An R Package for Deep Sequencing-Based Detection of Fetal Autosomal Abnormalities from Maternal Cell-Free DNA.

Authors:  Baohong Liu; Xiaoyan Tang; Feng Qiu; Chunmei Tao; Junhui Gao; Mengmeng Ma; Tingyan Zhong; JianPing Cai; Yixue Li; Guohui Ding
Journal:  Biomed Res Int       Date:  2016-06-29       Impact factor: 3.411

3.  Women's Attitudes Toward Invasive and Noninvasive Testing When Facing a High Risk of Fetal Down Syndrome.

Authors:  Valerie Seror; Olivier L'Haridon; Laurence Bussières; Valérie Malan; Nicolas Fries; Michel Vekemans; Laurent J Salomon; Yves Ville
Journal:  JAMA Netw Open       Date:  2019-03-01

Review 4.  Decision-making factors in prenatal testing: A systematic review.

Authors:  Valentina Di Mattei; Federica Ferrari; Gaia Perego; Valentina Tobia; Fabio Mauro; Massimo Candiani
Journal:  Health Psychol Open       Date:  2021-01-13

5.  Positive Attitudes towards Non-Invasive Prenatal Testing (NIPT) in a Swedish Cohort of 1,003 Pregnant Women.

Authors:  Ellika Sahlin; Magnus Nordenskjöld; Peter Gustavsson; Josephine Wincent; Susanne Georgsson; Erik Iwarsson
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

6.  Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I-clinical impact.

Authors:  Dick Oepkes; G C Lieve Page-Christiaens; Caroline J Bax; Mireille N Bekker; Catia M Bilardo; Elles M J Boon; G Heleen Schuring-Blom; Audrey B C Coumans; Brigitte H Faas; Robert-Jan H Galjaard; Attie T Go; Lidewij Henneman; Merryn V E Macville; Eva Pajkrt; Ron F Suijkerbuijk; Karin Huijsdens-van Amsterdam; Diane Van Opstal; E J Joanne Verweij; Marjan M Weiss; Erik A Sistermans
Journal:  Prenat Diagn       Date:  2016-11-15       Impact factor: 3.050

7.  The Knowledge, Attitude, Practices, and Satisfaction of Non-Invasive Prenatal Testing among Chinese Pregnant Women under Different Payment Schemes: A Comparative Study.

Authors:  Wenjun Zhu; XiaoXiao Ling; Wenru Shang; Jiayan Huang
Journal:  Int J Environ Res Public Health       Date:  2020-09-30       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.